Amgen finds no synergy with Synergen

Noteworthy

In 1994, Amgen Inc. acquired Synergen Inc.'s product pipeline and $120 million in cash for $240 million. Nearly three years later, nothing in that pipeline has progressed past Phase I/II testing, and now AMGN is looking for a partner to help share the costs of developing all but one product candidate.

The

Read the full 537 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE